Top brokers name 3 ASX shares to buy next week

Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

| More on:
A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was another busy week for Australia's top brokers. This led to the release of a large number of broker notes.

Three ASX broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

AGL Energy Limited (ASX: AGL)

According to a note out of UBS, its analysts have retained their buy rating on this energy giant's shares with a slightly reduced price target of $11.25. UBS was pleased with AGL's first half result, noting that it was well ahead of the broker's expectations. It sees potential for further earnings outperformance in the coming years if its generation availability can be maintained. The AGL share price ended the week at $8.63.

CSL Ltd (ASX: CSL)

A note out of Morgans reveals that its analysts have retained their add rating on this biotechnology giant's shares with a trimmed price target of $315.40. This follows the release of a solid half-year result which revealed earnings ahead of consensus expectations. Overall, Morgans was pleased with the result and especially the performance of the key CSL Behring business. And although the broker has trimmed its valuation to reflect the CSL112 trial failure, it continues to see a lot of value on offer. The CSL share price was trading at $284.00 at Friday's close.

Pro Medicus Limited (ASX: PME)

Analysts at Macquarie have retained their outperform rating and $120.00 price target on this health imaging technology company's shares. Macquarie notes that Pro Medicus fell short of the broker's first-half expectations with both its revenue and earnings. However, it remains positive given new contract wins and its healthy sales pipeline. The Pro Medicus share price was trading at $87.24 on Friday.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Four people on the beach leap high into the air.
Broker Notes

4 ASX All Ords shares offering 10% to 30% annual growth: brokers

These ASX All Ords stocks have caught the eye of brokers this week.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Here are 2 ASX shares that Morgans rates as buys

Let's see why the broker is feeling bullish on these stocks.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Guess which ASX 200 stock was just upgraded to a buy rating

Why did the broker just turn bullish? Let's find out.

Read more »

Two brokers analysing stocks.
Broker Notes

Don't miss these changes to broker ratings on ASX shares

The verdicts are in.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why now is the time to buy this beaten down $8b ASX 200 stock

Goldman Sachs thinks that now is the time to invest in this beaten down drinks giant.

Read more »

a man sits alone in his house with a dejected look on his face as he looks at a glass of red wine he is holding in his hand with an open bottle on the table in front of him.
Broker Notes

Red alert! 4 ASX All Ords shares just got broker downgrades

These ASX All Ords stocks have caught the attention of brokers for all the wrong reasons.

Read more »